Pirh2 (p53-induced RING-H2 domain protein; also known as Rchy1) is an E3 ubiquitin ligase involved in a negative-feedback loop with p53. Using NMR spectroscopy, we show that Pirh2 is a unique cysteine-rich protein comprising three modular domains. The protein binds nine zinc ions using a variety of zinc coordination schemes, including a RING domain and a left-handed b-spiral in which three zinc ions align three consecutive small b-sheets in an interleaved fashion. We show that Pirh2-p53 interaction is dependent on the C-terminal zinc binding module of Pirh2, which binds to the tetramerization domain of p53. As a result, Pirh2 preferentially ubiquitylates the tetrameric form of p53 in vitro and in vivo, suggesting that Pirh2 regulates protein turnover of the transcriptionally active form of p53.
Tumor suppressor p53 is known for its prominent role in safeguarding genome integrity and preventing tumorigenesis. It induces cell cycle arrest or apoptosis in response to diverse cellular stresses, thus stopping damaged cells from proliferating 1, 2 . The cellular levels of p53 are tightly regulated by several ubiquitin E3 ligases that promote ubiquitylation of p53 and its subsequent targeting for 26S proteasome-dependent protein degradation 3 . Mdm2 is the prototypic p53 E3 ligase and a key negative regulator of p53 (ref. 4) . Mdm2 is overexpressed in a variety of human malignancies and is a target for development of therapeutic compounds that could inhibit its activity and promote p53-dependent apoptosis in cancers overexpressing Mdm2 (ref. 5) . The recent identification of several new p53 E3 ligases, namely Pirh2, COP1, TOPORS and ARF-BP1, adds more complexity to the p53 ubiquitylation pathway [6] [7] [8] [9] and may expand the potential targets for p53-dependent cancer therapies. However, the structural and catalytic properties of these new ligases and their physiological significance remain to be determined.
Pirh2 is a p53-inducible E3 ligase with a RING-H2 domain and has been shown to ubiquitylate p53 in vivo and in vitro 6 . Like Mdm2, Pirh2 is a negative regulator of p53. Overexpression of Pirh2 decreases p53 levels in the cell and represses p53-dependent transactivation and growth inhibition. Abrogation of Pirh2 results in a steady increase in p53 levels. Pirh2 has been shown to be overexpressed in a mouse lung tumor model and in human lung cancers 10 . The overexpression of Pirh2 is concomitant with decreased p53 levels in malignant tissues and independent of Mdm2, suggesting a role for Pirh2 in tumorigenesis through regulation of p53 stability 10 .
To understand the molecular mechanism of Pirh2-mediated regulation of p53 stability, we determined the solution structures of the three individual domains of human Pirh2 using NMR spectroscopy. Pirh2 contains a total of nine zinc binding sites, with six located at the N-terminal domain (NTD), two in the RING domain and one in the C-terminal domain (CTD). The nine zinc binding sites comprise three different zinc coordination schemes: RING-type cross-brace zinc coordination, C4 zinc finger and a left-handed b-spiral zinc binding motif formed by three recurrent CCHC sequence motifs. We also report that Pirh2 interacts with p53 through the CTD, which targets the p53 tetramerization domain (TET), with possible enhancement from a weak interaction between the NTD and the p53 DNA binding domain (DBD). We found that Pirh2 preferentially ubiquitylates the tetrameric form of p53 in vitro and in vivo, implying a role for Pirh2 in downregulating the transcriptionally active form of p53. Our study provides a structural basis and a molecular mechanism for the function of Pirh2 in regulation of the p53 ubiquitylation pathway.
RESULTS

Solution structure of Pirh2
Human Pirh2 is a 261-residue protein containing three domains: the NTD (residues 1-137), the central RING domain (residues 138-189) and the CTD (residues 190-261; Fig. 1a ). There are 29 cysteine residues throughout the protein, with 19 clustered in the NTD, 6 in the RING domain and 4 in the CTD (Fig. 1b) . Full-length Pirh2 protein could only be purified and studied at low concentrations (o50 mM) and was therefore not amenable to structural studies under a variety of conditions. However, we were able to prepare suitable NMR samples for the three individual domains of human Pirh2 and solve their solution structures using 3D heteronuclear NMR spectroscopy. We determined the zinc coordination and binding stoichiometries of Pirh2 based on the inductively coupled plasma atomic emission spectroscopy analysis and NMR restraints. The ensembles of the 20 lowest-energy conformers for these three domains are shown in Cys122, His134 and Cys136 for the sixth ion (Fig. 2a) . The overall structure of the human Pirh2 NTD is very similar to that of the mouse Pirh2 NTD (PDB 2DKT), with an r.m.s. deviation value of 1.274 Å (Ca atoms of residues 18-119), in agreement with their highly conserved sequences (80% identity). Comparison with known protein structures using the DALI server 11 did not reveal any other homologous folds.
Solution structure of the Pirh2 RING domain The Pirh2 RING domain folds into a globular structure that binds two zinc ions in a typical cross-brace arrangement. Two interleaved zinc binding sites are situated at opposite sides of the domain, with the seventh zinc ion coordinated by Cys145, Cys148, His169 and Cys172 and the eighth zinc ion bound by Cys164, His166, Cys183 and Cys186 (Fig. 2b) . The RING domain structure of Pirh2 is similar to that of other proteins. Notably, the distance between two zinc ions is 14.9 Å , a value close to the distances (B14 Å ) reported for the RING domain structures of PML (PDB 1BOR) and IEEHV (PDB 1CHC), reflecting conservation of the zinc binding motif in the RING domain protein family 12 . The Pirh2 RING domain is structurally homologous to, among others, the RING domain of Rbx1 from the SCF ubiquitin ligase complex (PDB 1LDJ), with an r.m.s. deviation value of 2.2 Å over 44 aligned Ca atoms; the BRCA1 RING domain (PDB 1JM7), with an r.m.s. deviation value of 1.9 Å over 43 aligned Ca atoms; and the rice transcription regulator EL5 RING finger structure (PDB 1IYM), with an r.m.s. deviation value of 3.2 Å over 47 aligned Ca atoms. Superposition of the four RING domain structures revealed substantial structural similarity in the zinc binding motif, the central b-sheet (b13 and b14) and the a2 helix, despite limited sequence identity (15-20%) between the RING domains of these proteins. Pro146, Ile147, Leu149, Leu168, Tyr173, Met176, Tyr181, Pro184, Leu185 and Met187 form a hydrophobic patch along a shallow depression on the molecular surface (see Supplementary Fig. 2 online), a feature shared with the E2 binding sites of other RING domains, such as that of c-Cbl 13 .
Solution structure of the Pirh2 CTD The structure of the Pirh2 CTD consists of a 30-residue disordered loop (residues 187-215) followed by a compact, globular fold that incorporates a single zinc ion with four cysteine thiol groups (Cys222, Cys225, Cys240 and Cys243) forming a tetrahedral zinc coordination site (Fig. 2c) . Residues 198-205 within the unstructured region showed some a-helical propensity, as indicated by their backbone NMR resonances. However, the NOE pattern in this region did not support the existence of any rigid structure, suggesting that this region is natively disordered and becomes an ordered a-helix under certain conditions, such as binding. The globular core comprises a twisted, three-stranded b-sheet (residues 216-223, 227-233 and 247-251), (b) Multiple sequence alignment of Pirh2 from eukaryotic organisms, with secondary structure elements of human Pirh2 indicated above. Arrows, b-strands; solenoids, a-helices; asterisks, zinc coordinating cysteine and histidine residues. Secondary structure elements are colored in gray, blue and brown, representing NTD, RING and CTD, respectively. Alignment was generated by ClustalW and was printed using the ESPript 2.2 software package 35 .
with the three strands arranged in the order b2, b1, b3. Comparison with known protein structures using the DALI server 11 did not reveal any significant homologous folds (z score 4 2.0). However, the topology resembles that of the zinc motif in domain B of the minichromosome maintenance complex (PDB 1LTL), with an r.m.s. deviation value of 4.2 Å for 51 Ca atoms, and that of the zinc ribbon in NOP10 of the H/ACA ribonucleoprotein complexes (PDB 2EY4), with an r.m.s. deviation of 2.2 Å for 30 Ca atoms. As both zinc motifs are involved in mediating complex formation, the C4 zinc finger of the Pirh2 CTD may also function as a protein interaction module. To better understand the structure of full-length Pirh2, we expressed the protein as an N-terminal glutathione S-transferase (GST) fusion protein with a thrombin cleavage site. We purified this protein in solution and removed the GST to yield a stable full-length Pirh2 that was soluble and active (see below) at concentrations o50 mM. Fulllength Pirh2 eluted from a size-exclusion column as a single peak of B35 kDa, indicating that Pirh2 is a monomer in solution. To assess whether the full-length protein contained interdomain interactions, we titrated individual 15 N-labeled domains with an unlabeled domain while monitoring the 15 N NMR resonances. We did not observe changes in resonance frequencies for any of the three domains when mixed with a two-fold excess of either of the other two domains (data not shown), implying that the full-length protein contains three relatively independent domains.
p53 interacts with both N-and C-terminal domains of Pirh2
To elucidate the molecular basis for the Pirh2-p53 interaction, we conducted protein-protein interaction studies in which full-length His 6 -tagged p53 was assayed against full-length Pirh2 and its three individual domains, each fused to GST (GST-Pirh2, GST-NTD, GST-RING and GST-CTD). p53 interacted with full-length GST-Pirh2, GST-NTD and GST-CTD, but not GST-RING. Given the amounts captured by the GST fusions, p53 seemed to bind to full-length Pirh2 slightly better than to the Pirh2 NTD or CTD (Fig. 3a) . To identify the region of p53 responsible for binding to Pirh2, we tested the interactions between two GST-Pirh2 proteins (GST-NTD and GST-CTD) and four p53 fragments: the N-terminal 70 residues, the DBD, the TET domain and C-terminal residues 355-393. The Pirh2 NTD interacted with the p53 DBD, whereas the Pirh2 CTD bound to the p53 TET domain (Fig. 3b) , suggesting that Pirh2 targets p53 by binding to two different sites of p53.
To confirm these observations and to map the p53 interaction sites on the NTD and CTD of Pirh2, we collected a series of 2D 1 H-15 N HSQC NMR spectra of the Pirh2 NTD and CTD and compared them in the absence or presence of the appropriate domains of p53. After adding an increasing amount of p53 DBD to 15 N-labeled Pirh2 NTD, we observed perturbations for the backbone amide resonances of His70, Ala71 and Glu76 and for the side chain NE2 of Gln72 (see Supplementary Fig. 3 online). These residues are all located close to the loop that binds the third zinc ion in the hinge region of the Pirh2 NTD and are conserved in mammals (Fig. 3c) . However, complex formation was not saturated under the conditions of our NMR experiments (0.6 mM p53 DBD), and further titration data points could not be generated because of solubility limitations. Thus, the interaction of the p53 DBD with the Pirh2 NTD is very weak (estimated K d 4 0.6 mM, compared to K d for Pirh2 CTD-p53 TET interaction (see below)), consistent with the substoichiometric binding observed in the protein-protein interaction experiments described above.
To characterize the interaction between the p53 TET domain and the Pirh2 CTD, we collected HSQC spectra of 15 N-labeled Pirh2 CTD in the absence or presence of p53 TET. After addition of p53 TET, we observed resonance perturbations for the Pirh2 CTD, with an estimated K d of 0.6 mM, confirming a weak interaction between these two domains. The affected residues of the Pirh2 CTD include the backbone amide groups of Ala249, Ala251, Arg254, Arg255 and Ile256 (see Supplementary Fig. 4a online) . Additionally, the line width for Gly252 and Gly253 were broadened beyond the detection limit, suggesting the involvement of these two residues in the complex formation. These residues define a molecular surface on the Pirh2 CTD for interaction with p53 TET (Fig. 3d) . p53 is transcriptionally active as a tetramer that is thought to form when p53 protein concentrations increase in response to various stress stimuli 14 . To investigate whether other oligomeric forms of p53 affect its interaction with Pirh2, we tested a dimeric TET domain mutant, M340Q L344R (p53DM), and a monomeric mutant, L344P (p53MM), under the same conditions used for the wild-type p53 TET domain 15 . No changes were observed for Pirh2 CTD NMR resonances after mixing with a two-fold excess of p53DM or p53MM, suggesting that Pirh2 does not bind the dimeric or the monomeric oligomerization domains of p53 (see Supplementary Fig. 4b,c) .
Pirh2 RING interacts with UBE2D2
To map the interactions between the ubiquitin conjugating enzyme E2 and Pirh2, we monitored the NMR resonances of the 15 N-labeled Pirh2 RING domain after addition of ubiquitin conjugating enzyme E2D2 (UBE2D2; also known as UbcH5b; Fig. 4) . We observed the most perturbation in two zinc coordination sites, including Ile147 and Cys148 from zinc-binding site I and Leu185 and Met187 from zinc binding site II. The residues from the central b-sheet and the helix, including Leu167, Leu168, Thr171, Glu174, Met176 and Tyr181, were also greatly perturbed. From this NMR titration data, we estimated the interaction between the Pirh2 RING domain and UBE2D2 to have a K d of 0.2 mM. Mutagenesis data of the most perturbed residues suggest that the hydrophobic patch on the RING domain surface mediates the RING-E2 interaction (data not shown). Notably, two RING domain mutants abrogated Pirh2 activity in a ubiquitylation assay (see below). The mutant M176E disrupted surface hydrophobicity and the RING-E2 interaction despite having an intact folded structure, and C186A affected zinc coordination, thereby disrupting the global structure of the RING domain, as evidenced by 15 N HSQC spectra of the mutants (data not shown).
Pirh2 catalyzes ubiquitylation of tetrameric p53
To characterize the E3 ligase activity of Pirh2, we carried out an in vitro ubiquitylation assay using recombinant GST-tagged full-length Pirh2 (GST-Pirh2) in a reaction containing E1, E2 (UBE2D2) and His-tagged ubiquitin, with or without recombinant p53 protein.
Ubiquitylation of Pirh2 and p53 was readily detected and was dependent on the presence of E1, E2, ubiquitin and Pirh2 (see Supplementary Fig. 5 online) . This is consistent with a previous finding that Pirh2 catalyzes autoubiquitylation and ubiquitylation of p53 (ref. 6) .
To investigate the contribution of individual p53 residues to ubiquitylation activity, we tested a series of p53 mutants in in vitro ubiquitylation assays, including three p53 DBD hot-spot point 
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mutants (R273H, R175H and E285A), two TET domain point mutants (p53DM and p53MM) and four deletion mutants (residues 1-360, residues 1-320, D325-355 (TET domain deleted) and D70-311 (DBD deleted); Fig. 5a ). In assays for Pirh2-mediated p53 ubiquitylation, the ubiquitylation levels and patterns of the p53 DBD mutants were similar to those of wild-type p53. The p53 deletion mutants 1-360 and D70-311 were also readily ubiquitylated by Pirh2. However, all p53 point and deletion mutants involving the TET domain had substantially diminished ubiquitylation levels, strongly suggesting that a properly folded tetrameric TET domain is required for ubiquitylation of p53 by Pirh2 (Fig. 5b) .
Pirh2 downregulates tetrameric p53 in vivo
The observation that Pirh2 selectively targets tetrameric p53 in vitro prompted us to test the interaction of Pirh2 with various oligomeric forms of p53 in vivo. We cotransfected Pirh2 or empty vector (pCDNA3(neo)) with wild-type p53, p53DM or p53MM into p53-null H1299 cells, which we collected after 40 h. We then assessed levels of wild-type p53, p53DM and p53MM by western blotting with antibody to the N terminus of p53, and we evaluated Pirh2-cotransfected versus empty vector-transfected cultures by pairwise comparison. As expected, in cells transfected with Pirh2, wild-type p53 amounts decreased to 20% of those in cells transfected with empty vector. This is consistent with the role of Pirh2 as an E3 ligase and a negative regulator of p53. However, the p53DM and p53MM levels were only decreased to 60% and 80% respectively, suggesting that dimeric p53 is less sensitive to Pirh2 levels, with monomeric p53 having the least sensitivity (Fig. 5c) . These data clearly indicate that Pirh2 efficiently targets and degrades tetrameric p53, the transcriptionally active form of p53 in the cell.
Pirh2 CTD is required for p53 ubiquitylation
To investigate the sequence determinants for Pirh2 autoubiquitylation and ubiquitylation of p53, we created a series of deletion mutants by systematically truncating the N-and C-termini of Pirh2 (Fig. 6a) . The truncation mutants were designed to test not only the contributions of the three globular regions observed in the NMR structures, but also the disordered regions of the CTD and residues 120-138 that are reported to be responsible for interaction with p53 (refs. 6,16). We expressed all deletion mutants in Escherichia coli, purified them as GST fusion proteins and tested them for ubiquitylation activity as we did for wild-type Pirh2. In Pirh2 autoubiquitylation assays, residues 120-261 and 1-195 showed activity similar to that of wild-type Pirh2, whereas no autoubiquitylation was detected in other fragments (Fig. 6b) . When the film was overexposed, we observed faint ubiquitylated species for fragments containing the intact RING domain (data not shown). No autoubiquitylation was detected for residues 1-137 under any conditions, consistent with the requirement of the RING domain. In contrast, Pirh2-mediated ubiquitylation of p53 was only observed for wild-type Pirh2 and the Pirh2 residues 120-261, 138-261 and 138-253 ( Fig. 6c-e) . The CTD deletion mutants and the RING domain mutants C186A and M176E showed no p53 ubiquitylation activity, indicating that the RING and most of the CTD are required for p53 ubiquitylation, whereas the NTD is not. The Pirh2 fragment of residues 138-253 retains the overall structural fold of the C-terminal zinc binding module but lacks residues 254-256, which are involved in p53 contact. This mutant was considerably less active than wild-type Pirh2 and Pirh2 residues 120-261 and 138-261, further supporting the role of the Pirh2 CTD in mediating p53 interaction. Although the NTD is clearly not required for p53 ubiquitylation, the weaker activity of Pirh2 residues 120-261 and 138-261 relative to wild type suggests that the NTD contributes to optimal Pirh2 activity through its weak interaction with the p53 DBD.
DISCUSSION
The structures of Pirh2 domains reveal several features in protein architecture and zinc coordination. An unusually high content of cysteine (11%) and histidine (8%) enables the coordination of nine zinc ions within this medium-sized protein. The N-terminal lobe of the Pirh2 NTD is a member of the CHY zinc finger family (Pfam PF05495), by virtue of its N-terminal CxHY sequence motif, and is found only in eukaryotes. The structure of the N-terminal lobe shows Reaction products were resolved on a 7.5% SDS-PAGE gel for lanes 1-10 and a 10% gel for lanes [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Detection of p53 ubiquitylation is described in Methods. (c) Pirh2 expression results in reduced levels of tetrameric p53 in vivo. H1299 cells were transfected with fulllength Pirh2 or empty vector (pcDNA3(neo)), along with either tetrameric (WT), dimeric (p53DM) or monomeric (p53MM) p53. Equal amounts of cell lysate were analyzed by SDS-PAGE, and amounts of p53, Pirh2 and b-actin were detected by immunoblotting. Levels of wildtype p53, p53DM and p53MM were quantified as ratios of p53 intensity to b-actin intensity. For each empty vector control experiment, p53 level was normalized to 1 to reflect the background level of endogenous Pirh2 activity against each type of transfected p53. Levels of wild-type p53, p53DM and p53MM in Pirh2-cotransfected cells are shown as intensity ratio relative to the appropriate control experiment.
a unique zinc coordination that combines a cross-brace zinc binding motif with a C4 zinc finger. The cross-brace zinc binding motif uses the consensus sequence CxHx(10)CCx(5)Cx(2)CHx(5)H to chelate two zinc ions. Although the topology of this cross-brace zinc binding motif in the NTD seems to be the same as that of the RING domain, the permutation and spacing of the cysteine and histidine residues for the zinc coordination are very different from those of the RING domain. The typical RING finger (Pfam PF00097) uses the consensus sequence Cx2Cx(9-39)Cx(1-3)Hx(2-3)Cx2Cx(4-48)Cx2C to bind two zinc ions and inevitably contains a hydrophobic patch for the recruitment of ubiquitin E2 ligases 12, 17 . Both of these features are lacking in the Pirh2 NTD, explaining the lack of E3 ligase activity in the N-terminal lobe despite its structural similarity to the RING domain.
The C lobe of the Pirh2 NTD folds into a three-turn b-spiral held together by three zinc ions. The structure is unique in two respects. First, this left-handed solenoid structure is made of three successive strand-turn-strand motifs. These motifs are packed together by a combination of zinc ion coordination and hydrophobic interactions between side chains from the strands. Second, the three zinc ions are interlocked by the sequence motif Cx(2)Cx (10)HCx (2)Cx (2)Cx (9)HCx (2)Cx (2) Cx (8)HxC, and in which the first histidine and fourth cysteine residues of each HCCC repeat are paired with the N-terminal cysteine pair to coordinate a zinc ion, while the second and third cysteine residues are paired with the C-terminal histidine and cysteine residues to bind another zinc ion (Fig. 2b) . This type of zinc coordination has not been previously reported and is conserved in eukaryotes. Protein sequence alignment revealed that many eukaryotic proteins contain similar sequence motifs (see Supplementary Fig. 6 online). All of these proteins have the HCCC repeats, and the spacings within the HCCC repeats are conserved, suggesting that these proteins also hold the b-solenoid zinc finger structure.
Our data indicate that the three domains of Pirh2 are independently folded and do not interact with one another, suggesting that the full-length protein has a modular arrangement of domains. The linker between the Pirh2 NTD and the RING domain is relatively short (B10 residues), suggesting that the NTD and the RING domain form a more rigid connection. In contrast, the linker between the RING domain and the CTD (B30 residues) gives Pirh2 great flexibility to bring together the ubiquitin-charged E2 enzyme with substrates.
p53 is a known substrate of Pirh2. We found that Pirh2 interacts with p53 primarily through CTD residues 249-256, which recognize the p53 TET domain with a K d on the order of 600 mM. The NTD of Pirh2 binds more weakly to the DBD of p53 and is not required for activity, although it may contribute to optimal activity. The region between the N-terminal CHY zinc finger and the RING domain of Pirh2 (residues 120-137) is reported to be required for p53 recognition because a mutant Pirh2 lacking residues 120-137 was unable to bind p53 (ref. 6) . In view of the present Pirh2 domain structures, this deletion disrupts both the fifth and sixth zinc coordinating residues and results in a markedly disturbed Pirh2 fold. Synthetic Pirh2 peptides derived from the same region (residues 120-130 and 126-137) bind very weakly (K d 4 1 mM) under physiological ionic strength conditions, implicating a weak and transient interaction between this Pirh2 peptide motif alone and p53 (ref. 16 ). Notably, we did not observe a direct interaction between Pirh2 residues 120-137 in the context of the full-length protein or folded individual domains, suggesting that prior reports of this interaction resulted from improper folding of the NTD. The binding site on Pirh2 for the E2 ligase UBE2D2 was mapped to the hydrophobic depression on the surface of the RING domain using NMR titration and mutagenesis. Given the NMR titration data, the Pirh2 RING domain binds UBE2D2 with an affinity of B200 mM, consistent with values observed for the other E2-E3 complexes 18 . These data confirmed the central role of the RING domain in recruiting the E2 and mediating p53 ubiquitylation, in a manner similar to known RING-E2 complexes 19, 20 .
Using an in vitro ubiquitylation assay, we found that the interaction of the Pirh2 CTD and p53 TET domain is essential for Pirh2-mediated p53 ubiquitylation. The Pirh2 fragment spanning residues 138-261, containing the RING domain and intact CTD but no NTD, was sufficient to ubiquitylate p53, whereas the Pirh2 fragments with C-terminal truncations had greatly reduced or no ubiquitylation activity. Notably, the fragment containing residues 1-195, which lacks the entire C terminus, was still able to mediate autoubiquitylation but not p53 ubiquitylation, suggesting that an intact Pirh2 C terminus is necessary for p53 ubiquitylation. Thus, the interaction of p53 through its TET domain with the CTD of Pirh2 seems to be necessary and sufficient for p53 ubiquitylation in vitro. The additional interaction of the p53 DBD with the Pirh2 NTD, although not required for ubiquitylation activity, seems to augment Pirh2-mediated p53 ubiquitylation. Further characterization of p53 mutants for their ability to be ubiquitylated by Pirh2 in vitro supported the importance of the tetrameric state of p53 in this activity; Pirh2 ubiquitylation of dimeric and monomeric mutants of p53 was severely curtailed. Mutations in the DBD of p53 had no effect on activity, again indicating a lesser role for this domain. Finally, we tested the p53 TET domain mutants for stability in H1299 cells when cotransfected with Pirh2. Consistent with the in vitro data, the levels of p53 oligomerization mutants were much higher than the level of wild-type protein, reflecting defects in protein degradation for the p53DM and p53MM mutants in the presence of Pirh2.
Together, these data suggest a working model for Pirh2-mediated p53 ubiquitylation in which the CTD-TET domain interaction provides the majority of the binding energy, and the NTD interacts transiently with one or more of the p53 DBDs (Fig. 7) . The combination of primary and secondary binding sites, together with the fact that wild-type p53 is tetrameric, may contribute to increased avidity and activity of the full-length proteins, as opposed to the individual domains studied here. This mode of interaction is likely to fix p53 with respect to the ubiquitin-charged E2, which docks at the central RING domain of Pirh2. Although the relative orientation of p53 domains is not likely to be rigid 21 , and the orientation of the Pirh2 domains is not yet known, this model is conceivable in that it places the C-terminal lysine resides of p53 near to the E2 active site. p53 ubiquitylation is thought to be the central cellular mechanism to downregulate p53 for proliferation in unstressed cells and to upregulate p53 in response to various stresses. As the main regulators of p53 stability, p53 E3 ligases have attracted enormous interest. They are often overexpressed in a variety of human malignancies and may represent a class of targets for the development of therapeutic compounds aimed at promoting p53-mediated growth inhibition and apoptosis in cancer cells. Mdm2 has been a therapeutic target and the subject of drug discovery activities in both academia and industry 5 . Notably, Pirh2 binds to domains distinct from the transactivation domain recognized by Mdm2, possibly offering an alternative (or additional) strategy for p53 regulation. The structures and interaction data presented here provide insight into the molecular mechanism of Pirh2-mediated p53 ubiquitylation and point to the disruption of the p53 TET-Pirh2 CTD interaction as a potential strategy for development of therapeutics.
METHODS
Protein preparation. Full-length Pirh2 and the Pirh2 NTD (residues 1-137), RING domain (residues 138-189) and CTD (residues 137-261) were PCR amplified and cloned between NdeI and BamHI of the pGEX2TK vector (GE Healthcare). Proteins were expressed in E. coli strain BL21 (DE3; Stratagene) for 5 h at 25 1C after induction with 1 mM IPTG. For unlabeled proteins, bacteria were grown in LB medium. For uniformly 15 N-and 13 C-labeled proteins, bacteria were grown in M9 minimal medium supplemented with 15 N-labeled ammonium chloride (0.8 g l -1 ), 13 C-labeled glucose (2 g l -1 ) and l50 mM ZnSO 4 . All Pirh2 proteins were purified by standard GST-affinity chromatography. The Pirh2 proteins were further treated with thrombin and purified by size-exclusion chromatography using a HiLoad 26/60 Superdex-75 column (GE Healthcare) to remove the GST tag. The final NMR samples were prepared in buffer D containing 50 mM sodium phosphate (pH 7.0), 150 mM KCl, 10 mM ZnCl 2 and 2 mM DTT at a concentration of 0.8 mM with 10% v/v D 2 O.
Full-length human p53, three p53 DBD mutants (R273H, R175H and E285A), two TET domain mutants (M340Q L344R (p53DM) and L344P (p53MM)) and four deletion mutants (residues 1-360, residues 1-320, D325-355 and D70-311) were cloned into the pET15b vector (Novagen), expressed as His 6 -tagged fusion proteins and purified using standard metal affinity purification procedures. UBE2D2 was cloned into the pET15b vector, expressed and purified as described for p53 proteins.
NMR spectroscopy and data analysis. NMR spectra were recorded at 25 1C on Varian INOVA 500-MHz or 600-MHz spectrometers equipped with tripleresonance cold probes and Bruker Avance 500-MHz or 800-MHz spectrometers Figure 7 Model of a potential ternary complex between Pirh2, p53 and the E2 enzyme UBE2D2. Top, domains of tetrameric p53 interacting with those of Pirh2. UBE2D2-Pirh2 RING domain orientations are based on the crystal structure of the homologous complex formed between UBCH7 and the c-Cbl RING domain 20 . Bottom, active site cysteine of UBE2D2, charged with ubiquitin, is shown in red.
equipped with cryoprobes. The assignments of 1 H, 15 N and 13 C resonances of the RING domain were done by a conventional manual procedure based on HNCO, HNCACB, CC(CO)NH-TOCSY, HC(CO)NH-TOCSY and HCCH-TOCSY spectra 22, 23 . For NTDs and CTDs, the assignments of 1 H, 15 N and 13 C resonances were obtained by an ABACUS 24 approach using HNCO, CC(CO)NH-TOCSY, HC(CO)NH-TOCSY, (H)CCH-TOCSY and H(C)CH-TOCSY. NOE peaks were picked using manual procedures. The restraints for backbone j and c torsion angles were derived from chemical shifts of backbone atoms using TALOS 25 . No hydrogen bond restraints were used. The initial structures calculated using only dihedral angle and NOE distance restraints were used to determine the coordinating residues to each zinc ion. Additional distance restraints between zinc atoms and their ligands were used in the calculations of the final structure. These nonexperimental distance restraints were developed based on analysis of the geometrical properties of zinc binding sites observed in a dataset of high-quality protein crystal structures 26 . The nonexperimental distance restraints include 2.25-2.40 Å between Zn and Sg of Cys residues, 2.00-2.20 Å between Zn and Ne/Nd of His residues and 3.28-3.38 Å between Zn and Cb of Cys residues. The distances between Sg and Ne/Nd atoms that coordinate the same zinc atom were also restrained within bounds of 3.70-4.00 Å for Sg-Sg, 3.27-3.87 Å for Sg-Ne/Nd, and 3.27-3.78 Å for Ne-Ne, respectively. Automated NOE assignment 27 and structure calculations 28 were done using CYANA (version 2.1) according to its standard protocol. A total of 92%, 90% and 88% of NOESY peaks were assigned for the Pirh2 NTD, RING domain and CTD, respectively, after seven iterative cycles of automated structure calculation and NOE assignment. The final 20 lowest-energy structures were refined within the CNS package 29 by a short constrained molecular dynamics simulation in explicit solvent 30 ( Table 1 ). After refinement, 99.7% residues in the Pirh2 NTD, 99.5% in the RING domain and 99.6% in the CTD were in favorable or allowed regions of the Ramachandran plot. Resulting structures were analyzed using MOLMOL 31 , PROCHEK-NMR 32 and PSVS validation software 33 . Figures were prepared using MOLMOL 31 and PyMOL (DeLano Scientific). GST pull-down assays. Purified full-length p53 and p53 fragments were incubated with GST alone or a GST-Pirh2 fusion protein in an assay buffer containing 20 mM Tris (pH 8.0), 100 mM NaCl, 2 mM DTT and 5% v/v glycerol in a 1:1 molar ratio at 4 1C overnight in the presence of 50 ml of glutathioneSepharose beads (GE Healthcare). The mixture was transferred to a microcolumn and, after extensive washing with the assay buffer, bound proteins were eluted with 20 mM reduced glutathione and detected by SDS-PAGE and Coomassie staining.
In vitro ubiquitylation assay. Human ubiquitin activating enzyme E1 and His 6 -tagged ubiquitin were purchased from Boston Biochem. The ubiquitylation reaction was carried out in a volume of 20 ml in a buffer of 50 mM Tris (pH 7.6), 5 mM MgCl 2 , 2 mM ATP and 2 mM DTT. The reaction mixture typically contained 50 ng of E1 (Calbiochem), 100 ng of UBE2D2, 5 mg of ubiquitin (Sigma), 1 mg of Pirh2 for detection of autoubiquitylation on E3 and 0.5 mg of full-length p53 for detection of p53 ubiquitylation. After being incubated at 30 1C for 90 min, the reactions were stopped by addition of SDS-PAGE sample buffer and resolved on 7.5-10% SDS-PAGE gels. Ubiquitylated proteins were visualized and evaluated by western blotting using monoclonal antibodies to GST (GE Healthcare) for Pirh2 autoubiquitylation or p53 (PAb1801) 34 for p53 ubiquitylation.
Cell culture and DNA transfection. p53-null H1299 cells were cultured in MEM Alpha with 10% FBS and antibiotics and transfected overnight by calcium phosphate with 10 mg of empty pcDNA3(neo) or pcDNA3(neo)-human Pirh2, and 0.1 mg of pcDNA3(neo)-p53 (wild-type, p53MM or p53DM). Cells were collected 40 h after transfection using 1% v/v NP-40 lysis buffer. Western blots were done using antibodies to p53 (DO-1; Santa Cruz), Pirh2 (Bethyl Laboratories) and b-actin (Sigma). ImageQuant 5.2 was used to quantitate the expression levels from the western blots for p53 and b-actin.
Accession codes. Protein Data Bank: Coordinates for the Pirh2 NTD, RING and CTD domains have been deposited with accession codes 2K2C, 2JRJ and 2K2D, respectively.
Note: Supplementary information is available on the Nature Structural & Molecular Biology website.
